Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 115,528,392 shares of the biopharmaceutical company's stock after purchasing an additional 185,508 shares during the quarter. Vanguard Group Inc. owned about 9.27% of Gilead Sciences worth $10,671,358,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Southland Equity Partners LLC lifted its stake in Gilead Sciences by 3.6% in the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after buying an additional 110 shares in the last quarter. Berkshire Bank lifted its position in shares of Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after acquiring an additional 111 shares in the last quarter. CFO4Life Group LLC boosted its stake in shares of Gilead Sciences by 2.7% in the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock worth $394,000 after acquiring an additional 112 shares during the last quarter. GHP Investment Advisors Inc. increased its position in shares of Gilead Sciences by 1.1% during the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company's stock worth $1,049,000 after purchasing an additional 122 shares in the last quarter. Finally, J.W. Cole Advisors Inc. raised its stake in Gilead Sciences by 1.0% in the 4th quarter. J.W. Cole Advisors Inc. now owns 13,597 shares of the biopharmaceutical company's stock valued at $1,256,000 after purchasing an additional 135 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Remove Ads

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the company's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on GILD shares. Piper Sandler boosted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Oppenheimer raised their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 4th. Wells Fargo & Company lifted their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday. Finally, The Goldman Sachs Group raised their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $105.12.

Gilead Sciences Stock Up 1.7 %

Gilead Sciences stock traded up $1.89 during trading on Thursday, reaching $111.16. The stock had a trading volume of 6,382,732 shares, compared to its average volume of 6,806,689. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The stock has a market cap of $138.43 billion, a PE ratio of 300.43, a P/E/G ratio of 0.71 and a beta of 0.21. The business has a 50 day moving average price of $105.08 and a 200 day moving average price of $94.58.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences's payout ratio is 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.